Details of the Drug Therapeutic Target (DTT)

General Information of Drug Therapeutic Target (DTT) (ID: TTLJX8E)

• DTT Name: KRas D816V mutant (KRAS D816V)
• Synonyms: K-Ras 2; Ki-Ras; c-K-ras; c-Ki-ras
• Gene Name: KRAS
• DTT Type: Clinical trial target; [1]
• UniProt ID: RASK_HUMAN
• TTD ID: T63185
• EC Number: EC 3.6.5.2
• Sequence:
  MTEYKLVVVGAGGVGKSALTIQLIQNHFVDEYDPTIEDSYRKQVVIDGETCLLDILDTAG
  QEEYSAMRDQYMRTGEGFLCVFAINNTKSFEDIHHYREQIKRVKDSEDVPMVLVGNKCDL
  PSRTVDTKQAQDLARSYGIPFIETSAKTRQRVEDAFYTLVREIRQYRLKKISKEEKTPGC
  VKIKKCIIM
• Function: Ras proteins bind GDP/GTP and possess intrinsic GTPase activity (PubMed:20949621). Plays an important role in the regulation of cell proliferation (PubMed:23698361, PubMed:22711838). Plays a role in promoting oncogenic events by inducing transcriptional silencing of tumor suppressor genes (TSGs) in colorectal cancer (CRC) cells in a ZNF304-dependent manner (PubMed:24623306). {ECO:0000269|PubMed:20949621, ECO:0000269|PubMed:22711838, ECO:0000269|PubMed:23698361, ECO:0000269|PubMed:24623306, ECO:0000305}.
• KEGG Pathway: 3845 (hsa)
• Reactome Pathway:
  (R-HSA-112412)
  (R-HSA-1169092)
  (R-HSA-1236382)
  (R-HSA-1250196)
  (R-HSA-1250347)
  (R-HSA-1433557)
  (R-HSA-167044)
  (R-HSA-171007)
  (R-HSA-179812)
  (R-HSA-180336)
  (R-HSA-186763)
  (R-HSA-1963640)
  (R-HSA-210993)
  (R-HSA-2179392)
  (R-HSA-2424491)
  (R-HSA-2428933)
  (R-HSA-2871796)
  (R-HSA-375165)
  (R-HSA-4086398 [P01116-2])
  (R-HSA-442982)
  (R-HSA-5218921)
  (R-HSA-5621575)
  (R-HSA-5637810)
  (R-HSA-5654688)
  (R-HSA-5654693)
  (R-HSA-5654699)
  (R-HSA-5654700)
  (R-HSA-5654704)
  (R-HSA-5654706)
  (R-HSA-5654712)
  (R-HSA-5654719)
  (R-HSA-5655253)
  (R-HSA-5655291)
  (R-HSA-5655302)
  (R-HSA-5655332)
  (R-HSA-5658442)
  (R-HSA-5673000)
  (R-HSA-5673001)
  (R-HSA-5674135)
  (R-HSA-5675221)
  (R-HSA-6802946)
  (R-HSA-6802948)
  (R-HSA-6802952)
  (R-HSA-6802953)
  (R-HSA-6802955)
  (R-HSA-74751)
  (R-HSA-8849471)
  (R-HSA-8851805)
  (R-HSA-8951936)
  (R-HSA-9026519)
  (R-HSA-9027284)
  (R-HSA-9028731)
  (R-HSA-9034864)
  (R-HSA-9607240)
  (R-HSA-9634285)
  (R-HSA-9634635)
  (R-HSA-9648002)
  (R-HSA-9649948)
  (R-HSA-9656223)
  (R-HSA-9664565)
  (R-HSA-9665348)
  (R-HSA-9665686)
  (R-HSA-9670439)
  (R-HSA-9673767)
  (R-HSA-9673770)
  (R-HSA-9674555)
  (R-HSA-9680350)
  (R-HSA-9703465)
  (R-HSA-9703648)
  (R-HSA-9753510)
  (R-HSA-9753512)

Molecular Interaction Atlas (MIA) of This DTT

1 Clinical Trial Drug(s) Targeting This DTT

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
ASP3082	DMDRXLL	Aggressive cancer	2A00-2F9Z	Phase 1	[1]

References

• [1] Protein degraders enter the clinic - a new approach to cancer therapy. Nat Rev Clin Oncol. 2023 Apr;20(4):265-278.